Abstract Since the majority of chemical carcinogens are not capable of causing hazardous effects per se, the metabolism of these compounds is a crucial part of the initial host response to the environmental ex p o s u re . Disturbances in the balance between activation and detox i f i c a t i o n may thus explain the individual variations in responses to ex p o s u res to carc i n o g e n s . The amount of the ultimate carcinogen produced depends on the action of competing activation and detox ification pathways involving cytochrome P450 and glutathione-S-tra n s f e rases enzymes.
I n t ro d u c t i o n Genetic factors in individual responses to environmental exposure
Ac c o rding to the recent advances in molecular e p i d e m i o l o g y, an emerging new field that combines highly sensitive and specific techniques for detecting early damage associated with c a n c e r, it has been possible to identify ri s k s and pre vent adverse health effects related to e n v i ronmental exposure s.
T h e re are approximately 500,000 cancer-related deaths annually in the United States; as many as 80% of those deaths could be pre ve n ted due to the fact that most malignancies are a result of external factors rather than inhere n t biological conditions (Eu b a n k s, 1994). By combining knowledge about external factors re l a ted to lifestyle and environmental or occupational exposure to chemicals with how genetic d i f f e rences cause va riations in human res p o n s e to environmental pollutants, it will be possible to answer questions like why certain groups of people have a higher incidence of cancer after e x p o s u re to a toxicant and others do not. Mo l ecular epidemiolgy is an emerging new field that combines highly sensitive molecular techniques for detecting early damage a s s o c i a t e d with cancer.
For this purpose, it is necessary to use biological markers as "indicators signaling eve n t s in biological systems or samples" ( National Res e a rch Council, 1987:3) . Us u a l l y, three types of biological markers are identified: the first is a b iological marker of exposure, or exposure biom a rk e r, that may be an exogenous compound (or a metabolite) within the body, an intera c t i ve p roduct between the compound (or metabolite) and an endogenous component, or another event related to the exposure. The second, a m a rker for the effect, which may be an endogenous component, or a measure of the functional capacity, or some other indicator of state or balance of the body or organ system, as affected by the exposure. Such effect markers are generally preclinical indicators of abnorm a l i t i e s. T h e t h i rd is a marker of susceptibility, whether inh e rited or induced, which serves as an indicator in that individual is particularly sensitive to the effect of a xenobiotic or to the effects of a gro u p of such compounds (Grandjean et al., 1994) .
Among all biomark e r s, the markers of susceptibility are particularly re l e vant to determining inherited predisposition to risk of adverse health effects as a result of exposure to e n v i ronmental chemicals. The underlying p ri nciple of this marker is the interindividual diff e rences that confer sensitivity or resistance to e n v i ronmentally induced disease. T h e re are t h ree types of susceptibility markers: the first is based on the fact that most chemicals are alt e red by enzymes and these alterations may inc rease or decrease the ability of a chemical to i n t e ract with tissue macromolecules such as DNA, RNA, or pro t e i n s. The balance betwe e n enzymes that activate and detoxify chemicals differs among individuals and ethnic gro u p s. A second type of susceptibility marker re f l e c t s genetic differences in the capacity of cells to repair DNA damage caused by environmental insult. People deficient in DNA repair genes may exhibit more DNA damage manifested as inc reased levels of DNA adducts; alterations in c h romosome number, stru c t u ral chro m o s o m e modification, activated oncogenes and their p rotein products and higher incidence of canc e r. A third type of susceptibility marker is preexisting inherited genetic defects that incre a s e the risk of cancer. If a person has inherited one or more of the necessary genetic altera t i o n s, f e wer steps are needed for a chemical to cause c a n c e r, putting this person at a greater risk. We will concentrate on the first one related to enzyme metabolism.
Susceptibility marker and enzyme m e t a b o l i s m
T h e re is considerable va riation among humans in the production of enzymes that either activate the formation of electrophilic metabolites that covalently bind to DNA or catalyze detox ification of chemical carcinogens (Ha r ri s, 1989; 1 9 9 1 ) .
Disturbances in the balance between activation and detoxification may thus explain the individual va riations in responses to exposure s to carcinogens (Hi rvonen, 1995) . In otherw o rd s, the interindividual va riation in response to xenobiotics and their potential carcinogenic effects is mediated by inherited predisposition (Sh i e l d s, 1994). Ce rtain individuals may be at significantly greater risk of chemically induced cancer than the ave rage individual due to marked differences in the activation and d e t oxification pro c e s s e s.
Many of the enzymes invo l ved in metabolic xenobiotic pathways have recently been show n to express genetic polymorphism in the population (Umeno et al., 1988; Id l e, 1991; Hi rvo n e n et al., 1993; Persson et al., 1993; Kato et al., 1 9 9 4 ; Bois et al., 1995; Raunio et al., 1995; Kroemer & Eichelbaum, 1995) .
The xenobiotic-metabolizing machinery contains two main types of enzymes: Phase Imediating ox i d a t i ve metabolism, and Phase II -conjugating enzymes. Many compounds are c o n ve rted to re a c t i ve electrophilic metabolites by the ox i d a t i ve Phase I enzymes, which are mainly cytochrome P-450 enzymes (CYPs ) . Phase II conjugating enzymes, such as glut a t h i o n e -S -t ra n s f e rase (GST), UDP-g l u c u ro n os y l t ra n s f e rases and N-acetyltra n s f e rases ( N AT) , act usually as inactivating enzymes (Raunio et al., 1995) .
The cytochrome P-450 gene superf a m i l y c a r ry out a myriad of diverse biotra n s f o rm ations including both anabolic and catabolic reactions (Wolf, 1986; Umeno et al., 1988) . Du e to the important role of cytochromes P450 in the metabolic activation of many pro c a rc i n og e n s, extensive re s e a rch in the past has focused on the relationship between the distri bution of polymorphic va riants of differe n t i s ozymes of P450 and cancer susceptibility. In this respect, three isozymes in particular have been studies: CYP1A1, CYP2D6, CYP2E1.
CYP genes and polymorphism
In recent ye a r s, increase attention has been focused on the possible relationship between int e rindividual differences in CYP gene stru c t u re and inducibility of CYP enzymes. This inform ation has been used for the evaluation of inc reased susceptibility for cancer. As a matter of fact, many of the different isoforms of P450 act i vate pre c a rcinogens and the interi n d i v i d u a l d i f f e rences in expression of P450 forms cause a p ronounced va riation in the level of the activated carcinogens in the cell.
It is not so long since it was believed that t h e re we re 2 cytochrome P450 enzymes, the m e t h y l c h o l a n t h rene-inducible P448 and the phenobarbitone-inducible P450. From cloned cDNA sequences, the deduced aminoacid sequences of some 57 P450 species have now been arri ved at (Id l e, 1991) . This is also a likely explanation if polymorphically distri b u t e d va riant forms of the isoz y m e, with differe n t catalytic pro p e rt i e s, occur within the population. P450 polymorphism in cancer susceptibility could also be lined to the fact that the P450 isozyme participates in the tra n s f o rm ation of endogenous compounds, which are imp o rtant during the process of differentiation of the initiated cell to the ultimate malignant s t a g e. A genetic linkage between P450 and carcinogenesis might also be found at the level of i n h e rited haplotypes, where an association could be related to linkage disequilibrium with c a n c e r-associated genes such as oncogenes and tumor supressor genes, located in the s a m e c h romosomal region (Rannug et al., 1995) .
The CYP1A is the gene encoding P4501A1, a P450 isozyme that catalyzes the oxidation of p o l yc yclic aromatic hyd rocarbons (PAHs) to phenolic products and epoxides (Go n z a l e s, 1989). The induction of CYP1A1 proceeds via binding of the inducer compound to the ary l h yd rocarbon (Ah) re c e p t o r, and the liganded receptor activates tra n s c ription of seve ra l genes that encode proteins invo l ved in xenobiotic metabolism.
The bioactivation of seve ral PAHs has been s h own to begin with stimulation of the aromatic hyd rocarbon (Ah) re c e p t o r, which then a c t ivates CYP1A1, epoxide hyd ro l a s e, and other enzymes (Hi rvonen, 1995) . Beside PA H s, CYP1A1 is also inducible by xenobiotics found in cru c i f e rous vegetables such as flavo n e s, and by indole deri va t i ves such as acid condensation products of indole-3-carbinol and phot o ox i d i zed deri va t i ves of tryptophan (Mc D o nnell et al., 1992) . Ad d i t i o n a l l y, studies in mice and rats have indicated that UV light induces CYP1A1 in the skin and in the liver (Rannug et al., 1995) .
The catalytic activities and the mode of i nduction of CYP1A1 appear to be ve ry, we l l c o n s e rved in higher animals, indicating that it has some important physiological function. The activity and inducibility pattern in humans of this enzyme, which forms DNA-re a c t i ve metabolites from PAH, is there f o re of great imp o rtance when assessing the cancer risk to hum a n s. CYP1A1 is considered to be pri m a rily an e x t rahepatic enzyme in humans. It is induced in lung, in lymphocytes, and in placenta after e x p o s u re to PAHs and tobacco smoke (Antilla et al., 1991 ).
• C Y P 2 D 6
The genetic polymorphism related to the antih y p e rt e n s i ve drug debrisoquine was the first one described associating the metabolism of d rugs with expression of a P450 enzyme. T h e gene CYP2D6 encodes P450IID6 or debri s oquine 4-hyd rox y l a s e, sometimes re f e r red to as P450dbl (Go n z a l e s, 1995).
The CYP2D6 polymorphism is one of the most thoroughly studied human enzyme defic i e n c i e s. A genetic polymorphism in the CYP2D6 gene locus affects 5-10% of the Caucasian population and is responsible for impaired de-b risoquine hyd roxylase activity (Hi rvo n e n , 1995). This polymorphism has conve n t i o n a l l y been determined by the administration of a test drug (usually debrisoquine) and subsequent analysis of the uri n a ry metabolic ra t i o. Ac c o rding to that, individuals have been class ified as poor metabolizers (PMs) or extensive m e t a b o l i zers (EMs) of debrisoquine (Id l e, 1991). Using polymerase chain reaction (PCR)-based analysis together with the (re s t ri c t i o n f ragment length polymorphism (RFLP) analys i s, the three most common defective alleles of CYP2D6 in Caucasians are CYP2D6A, a deletion of A2637 in exon 5 causing a frameshift mutation; CYP2D6B, a transition involving G1934 to A causing a splicing defect and CYP2D6D, w h e re a deletion of the entire CYP2D6 functional gene has occurred (Rannug et al., 1995) .
T h e re is a pronounced interethnic difference in the distribution of these defect alleles, w h e re the CYP2D6B and CYP2D6A alleles are almost exc l u s i vely present in the Ca u c a s i a n population. By contrast, the CYP2D6D allele is m o re evenly distributed between black, Asian, and Caucasian populations.
Se ve ral studies have shown that the extens i ve metabolizer (EM) phenotype is associated with increased risk of va rious cancers, especially tobacco-smoke-induced lung cancer ( Raunio et al., 1995) . Recent genotyping studies have either confirmed (Hi rvonen et al., 1993) or refuted (Rannug et al., 1995 ) such an a s s o c i a t i o n .
Ac c o rding to Raunio et al. (1995) , the ove rre p resentation of CYP2D6 EMs among lung cancer patients can be explained in two ways: first, the CYP2D6 may mediate the activa t i o n of pro c a rcinogenic agents present in tobacco s m o k e. The demonstration that CYP2D6 is capable of activating the tobacco-specific pro c a rcinogen 4-(methylinitro s a m i n o ) -1 -( 3 -py ri d y l ) -1-butanone (NNK), directly supports this hyp o t h e s i s. Second, the CYP2D6 gene may be in a linkage disequilibrium with the causative gene.
• C Y P 2 E 1
The cytochrome P4502E1 (CYP2E1) is a major ethanol-inducible P450 isozyme that metabol i zes a wide va riety of chemicals with differe n t s t ru c t u re s, particularly small and hyd ro p h i l i c compounds (Persson et al., 1993) . To d a y, more than 100 specific substrates for CYP2E1 have been identified, such as benze n e, dimethylnit ro s o a m i n e, and vinyl chloride all of them potentially important carcinogens (Rannug et al., 1995) . CYP2E1 is localized in seve ral differe n t t i s s u e s, among them the brain and lung, but the highest expression is in the live r. The regional distribution of CYP2E1 correlates well to the areas where the hepatotoxic chemicals, k n own to be activated by CYP2E1, exert their t oxic action (Persson et al., 1993) .
Polymorphism of CYP2E1 gene has re c e n t l y been shown to be one of the potential indicators of a cytochrome P450-associated susceptibility to cancer in man (Hi rvonen et al., 1993) . Genetic polymorphism, identified by RFLP using the re s t riction enzyme D ra I, Ps t 1, (R s a I) and Ta q I of CYP2E1 gene, have been shown to be associated with human cancer. In Ja p a n e s e, the distribution of two D ra I genotypes among lung cancer cases is significantly different fro m that among controls and an association was found to exist between the amount of lifelong smoking exposure and the distribution of the D ra I genotypes among lung cancer patients. Subsequent studies have revealed profound ethnic differences in the frequencies of the polymorphic alleles. In a study involving Fi n n i s h lung cancer patients, homozygosity for the ra re D ra I allele (minor, allele C) was found to be less frequent than in the Japanese population, and the distribution was similar among lung cancer patients and their controls (Hi rvonen et al., 1993) which is in agreement with the re s u l t s obtained by Persson et al. (1993) .
Another CYP2E1 polymorphism is identified by RFLP, using Ps t 1(R s a 1) is also identified. This re s t riction site is located in the tra n s c ri ption region of the gene and might have a biological effect (Kato et al., 1994) .
G S Ts genes and polymorphism
The glutathione S-tra n s f e rases (GSTs) are a family of multifunctional dimeric pro t e i n s which can conjugate electrophilic molecules with glutathione to render them less toxic and h a ve the additional pro p e rty of acting as binding proteins or ligandins in the liver (Id l e, 1991). Ca rcinogens detoxified by GSTs include p o l yc yclic aromatic hyd rocarbons present in the diet and tobacco smoke.
Human GSTs have been grouped on the basis of their isoelectric points into alpha (basic) mu(near-n e u t ral) and theta (acidic) form s. Members of the same class share 75-95% a m i n o acid similari t y, but between classes the identity d rops to 25-30%. It appears that while all human livers express seve ral alpha forms of GST, only about 50% of them express a mu isoz y m e ( Ma n n e rvik et al., 1992).
Within the human mu class there is a specific isozyme GSTM1 that is frequently lacking in about 40-45% among Ca u c a s i a n s, i.e., they 1 1
Cad. Saúde Pública, Rio de Janeiro, 14(Sup. 3):7-13, 1998 i n h e rit two deficient alleles and are homoz ygous for the null allele (Raunio et al., 1995) . T h e GSTM1 activity is lacking in about 38-65% of d i f f e rent ethnic populations (Bo a rd et al., 1 9 9 0 ) .
As DNA adducts formation is inversely correlated with GSTM1 expression, individuals missing GSTM1 may have reduced capacity to d e t oxify re a c t i ve metabolites (Se i d e g a rd et al ., 1990; Nakajima et al., 1995) . Hi rvonen et al. (1993) re p o rted that the GSTM1 null (GSTM1 0/0) genotype is associated with increased ri s k of squamous cell carcinoma of the lung. Ot h e r s found an association between adenocarc i n oma and lack of GSTM1 expression (Se i d e g a rd et al ., 1990; Bell et al., 1993) . Howe ve r, Bro c kmoller et al. (1993) did not find any significant c o r relation between GSTM1 genotypes and va rious types of lung cancer.
Individuals lacking GSTM1 could be at a g reater risk for developing cancer due to deficient detoxification pro c e s s e s. T h e re are, howe ve r, seve ral putative confounding factors that a re known to affect the phenotype, such as env i ronmental exposure s, nutrition and differences in smoking habits. Studies conducted by Hi rvonen et al. (1993) with Finnish lung cancer patients showed that 62 % of individuals with squamous cell carcinoma of the lung we re of the GSTM1 null genotype compared with 44% in the control population. Lack of the GSTM1 gene is also associated with susceptibility to b l a d d e r, skin and colon cancers (Raunio et al., 1 9 9 5 ) . Nakajima et al. (1995) recently re p o rt e d that patients lacking the GSTM1 gene have a less efficient pulmonary detoxification system than GSTM1 positive genotypes due to an ove rall low GST activity. Such individuals with the GSTM1 null genotype we re also found to exp ress significantly lower levels of the µ-class GSTM3-3 in the lung than individuals who possessed the GSTM1 gene. Antilla et al. (1991) rep o rted that all GST enzymes are most abundant in the ciliated epithelium of the bro n c h i , and least in the distal airw a y s. Fu rther analysis of the lung tissues by high perf o rmance liquid c h ro m a t o g raphy demonstrated that GST subunits A1, A2, M1, M3 & P1 we re present in va rying amounts with the different individuals studied. The lack of GSTs (especially among GST null individuals) in the bronchial wall could favor the development of SCC which ususally originates from the bronchial epithelium (Antilla et al., 1991) . Howe ve r, in view of the re l a t i vely high content of GSTP1 and GSTM3 and low content of GSTM1 in the lung, the influence of GSTM1 on susceptibility to lung cancer probably originates in extra p u l m o n a ry c o m p a rtments such as the liver where GSTM1 is the only active GST detected (Ra n d e rath et al., 1989). A considerable amount of PAHs fro m tobacco smoke passes into systemic blood to be activated or detoxified in extra p u l m o n a ry t i s s u e s, e.g. live r, and causes cancer in nonp u l m o n a ry tissues (Ra n d e rath et al., 1989 ). It is t h e re f o re reasonable to assume that more carcinogenic electrophiles enter the circ u l a t i o n f rom the liver in GSTM1 null individuals comp a red to GSTM1 +/+ individuals. This assumption is also consistent with the association of the GSTM1 null genotype with increased risk of other cancers such as the stomach, colon, urin a ry bladder and larynx (Lafuente et al., 1993; Anwar et al., 1996) .
Glutathione S-tra n s f e rase theta (GSTT1) is another polymorphic gene which is deleted in 38% of a Eu ropean population (Pemble et al., 1994) and 20% in No rth Americans (Nelson et al., 1995) . The deficiency is highly corre l a t e d with the inability to conjugate glutathione with small molecular weight tox i c a n t s. Howe ve r, its association with the development of cancer has not been adequately inve s t i g a t e d .
Since metabolism of chemicals re q u i res the i n t e ractions with multiple genes, inve s t i g a t o r s h a ve begun to document the inheritance of multiple polymorphic genes in the deve l o pment of cancer (Raunio et al., 1995) .
The frequency of the GSTT1 null genotype has not yet been studied extensive l y. T h re e studies have re p o rted that the null allele frequency ranged between 20.4% to 38% depending on the size and ethnicity of the studied population (Pemble et al., 1994; El -Zein et al., 1997; Ab d e l -Rahman et al., 1996) .
The association between the GSTT1 deletion and increased incidence of lung cancer can be explained in different ways. GSTT1 deficiency was shown to be responsible for inc reased induction of chromosomal damage by e p oxide substrates such as ethylene oxide i n v i t ro ( Hallier et al., 1993) .
Genetic predisposition and chro m o s o m e a b e r rations may be mechanistically re l a t e d to the initiation of lung carc i n o g e n e s i s. We p roved that lung cancer patients missing one or the other GST (GSTM1 or GSTT1) genes we re found to have significantly higher chro m o s o m e a b e r rations compared to lung cancer patients with both genes present (Co n f o rt i - Froes et al., 1997) . Ac c o rding of that, individuals lacking one or both genes are expected to have inc reased body burden of these toxic metabolites. Another possible mechanism is that cigare t t e smoke is known to contain multiple chemicals that are substrates for both GSTM1 and GSTT 1 gene pro d u c t s. T h e re f o re, the combined polymorphic deletion of the two genes is expected to interact positively to modify cancer risk.
Molecular epidemiology in Brazil
The molecular epidemiology in Brazil is a new field of expert i s e. De s p i t e, a great interest has been emerged in scientific community. In our l a b o ra t o ry we are currently searching the link b e t ween some types of cancer and enviro nmental exposure s. To better understand that re l a t i o n s h i p, we must know the brazilien distribution concerning the xenobiotic metabolizing genes, such as the CYPs and GSTs family. Ac c o rding of that, this is our first pri o rity ongoing project we are concentrated in order to h a ve those data soon. Along with, we are conducting two different studies re g a rding genetic susceptibility and environmental-cancer re l a t e d .
One of them concerns the link between hepatocellular carcinoma (HCC) and the polymorphic activating and detoxifying genes. T h e H CC is the most frequent malignant tumor of the liver and the commonest cancer occurri n g in males in the world. The annual incidence of the disease worldwide is estimated to be one million cases (Lau & Lai, 1990) . T h e re is a s t rong and specific association between chro nic hepatitis B and C virus infection and HCC . Hepatic cirrhosis due to alcohol is another aetiologic factor incriminated. Howe ve r, genetic p redisposition may also act to promote hepat o c a rc i n o g e n e s i s, once heavy drinkers do not always develop alcoholic liver disease (Ts u t s umi et al., 1994) and polymorphism of CYP2E1 may be related to liver disease incidence in Japanese population (Kato et al.,1995) .
The other ongoing project concerns the study of carcinogen-metabolizing enzymes and skin cancer. The genetic factors that mediate the pathogenesis of skin tumors is unk n own (Lear et al., 1996) . Skin cancers are the most common type of human neoplasia. Exc e s s i ve ultraviolet irradiation, with consequent re a c t i ve oxygen species attack on target molecules such as DNA, appears to be the major c a u s e, although the effects of UV are complex and other factors, including soot, cigare t t e s m o k e, and arsenic are re l e vant (He a g e rty et al., 1994). Co n s e q u e n t l y, polymorphism associated with impaired activation and detox i f i c ation may determine susceptibility to multiple skin cancers. In t e ractions between genetic predisposition and e n v i ronmental toxicants for development of lung c a n c e r. 
En v i ronmental Molecular Mu t a g e n e s i s,

